Sangamo Therapeutics (NASDAQ:SGMO) Earns Neutral Rating from Wedbush

Sangamo Therapeutics (NASDAQ:SGMO – Get Rating)‘s stock had its “neutral” rating reaffirmed by equities researchers at Wedbush in a research report issued to clients and investors on Friday, Zacks.com reports.

Several other analysts have also recently commented on SGMO. Stifel Nicolaus decreased their price objective on shares of Sangamo Therapeutics from $9.00 to $6.00 and set a “hold” rating for the company in a research note on Thursday, January 6th. StockNews.com cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Zacks Investment Research cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 13th. Finally, Truist Financial decreased their price objective on shares of Sangamo Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, April 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $13.50.

SGMO stock opened at $4.14 on Friday. The firm has a 50 day moving average of $5.41 and a 200 day moving average of $6.79. The stock has a market capitalization of $607.19 million, a PE ratio of -3.34 and a beta of 1.63. Sangamo Therapeutics has a 52 week low of $3.87 and a 52 week high of $12.83.

Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. The company had revenue of $28.20 million during the quarter, compared to analysts’ expectations of $27.29 million. Sangamo Therapeutics had a negative net margin of 161.05% and a negative return on equity of 42.04%. Sangamo Therapeutics’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the business earned ($0.32) EPS. Sell-side analysts anticipate that Sangamo Therapeutics will post -1.34 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ensign Peak Advisors Inc acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $34,000. C M Bidwell & Associates Ltd. acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $40,000. Point72 Hong Kong Ltd acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $46,000. Brown Advisory Inc. acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $76,000. Finally, Assenagon Asset Management S.A. acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $94,000. Hedge funds and other institutional investors own 52.40% of the company’s stock.

Sangamo Therapeutics Company Profile (Get Rating)

Sangamo Therapeutics, Inc, a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression.

Featured Stories